Trial
NCT03225547
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Chicago
Collaborators
—
Condition
Triple Negative Breast Neoplasms
Intervention
Pembrolizumab
Why stopped
side effects (rash)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-23